Assessing the functional significance of ecstasy-related memory deficits using a virtual paradigm

Human Psychopharmacology

Volumn 25, Issue 4, 2010, Pages 318-325

  Montgomery, Catharine ^a   Hatton, Nicholas P ^a   Fisk, John E ^b   Ogden, Ruth S ^a   Jansari, Ashok ^c  

^a LIVERPOOL JOHN MOORES UNIVERSITY   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

^c UNIVERSITY OF EAST LONDON   (United Kingdom)

Author keywords

Cannabis; Cocaine; Ecstasy; Executive function; Virtual reality

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; CANNABIS; COCAINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; EPWORTH SLEEPINESS SCALE; FEMALE; HUMAN; MALE; MEMORY DISORDER; MULTIPLE DRUG ABUSE; MULTIVARIATE ANALYSIS OF VARIANCE; OFFICE WORKER; PLANNING; PRIORITY JOURNAL; QUESTIONNAIRE; SLEEP PATTERN; TASK PERFORMANCE; VIRTUAL REALITY;

AMPHETAMINE-RELATED DISORDERS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; CENTRAL NERVOUS SYSTEM STIMULANTS; COCAINE; COCAINE-RELATED DISORDERS; EXECUTIVE FUNCTION; FEMALE; HALLUCINOGENS; HUMANS; MALE; MARIJUANA ABUSE; MEMORY DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; NEUROPSYCHOLOGICAL TESTS; PROBLEM SOLVING; PSYCHOMOTOR PERFORMANCE; YOUNG ADULT;

EID: 77953930060     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1119     Document Type: Article

References (49)

1. Amieva H, Phillips L, Della Salla S. 2003. Behavioral dysexecutive symptoms in normal aging. Brain Cognit 53: 129-132.
2. Baddeley AD. 1986. Working Memory. Oxford University Press: Oxford, UK.
3. Bartzokis G, Lu PH, Beckson M, et al. 2000. Abstinence from cocaine reduces high-risk responses on a gambling task. Neuropsychopharmacology 22: 102-103.
4. Battaglia G, Yeh SY, O'Hearn E, Molliver ME, Kuhar MJ, DeSouza EB. 1987. 3,4 methylenedioxymethamphetamine and 3,4 methylenedioxyamphetamine destroy serotonin terminals in rat brain: quantification of neurodegeneration by measurement of H-paroxetine labeled serotonin uptake sites. J Pharmacol Exp Therapeut 242: 911-916.
5. Chan R. 2001. Dysexecutive symptoms among a non-clinical sample: a study with the use of the Dysexecutive Questionnaire. Br J Psychol 92: 551-565.
6. Chaytor N, Schmitter-Edgecombe M. 2003. The ecological validity of neuropsychological tests: a review of the literature on everyday cognitive skills. Neuropsychol Rev 13: 181-197.
7. Cole J, Sumnall H, Grob C. 2002. Sorted: ecstasy facts and fiction. The Psychologist 15(9): 464-467.
8. Cole JC, Sumnall HR. 2003. Altered states: the clinical effects of Ecstasy. Pharmacol Therapeut 98: 35-58.
9. Edginton T, Dawkins L, Bradon L, Nikolla D, Herbert C, Jansari A. 2008. An investigation of the effects of nicotine on executive processes using a virtual reality environment. Brain Impair 9(2): 207.
10. Eslinger PJ, Damasio AR. 1985. Severe disturbance of higher cognition after bilateral frontal lobe ablation: patient EVR. Neurology 35: 1731-1741.
11. Fisk JE, Montgomery C. 2009. Evidence for selective executive function deficits in ecstasy/polydrug users. J Psychopharmacol 23(1): 40-50.
12. Fox HC, McLean A, Turner JJD, Parrott AC, Rogers R, Sahakian BJ. 2002. Neuropsychological evidence of a relatively selective profile of temporal dysfunction in drug-free MDMA ("ecstasy") polydrug users. Psychopharmacology 162: 203-214.
13. Fox HC, Parrott AC, Turner JJD. 2001. Ecstasy use: cognitive deficits related to dosage rather than self-reported problematic use of the drug. J Psychopharmacol 15: 273-281.
14. Gillberg M, Kecklund G, Akerstedt T. 1994. Relations between performance and subjective ratings of sleepiness during a night awake. Sleep 17: 236-241. (Pubitemid 24174455)
15. Heffernan TM, Jarvis H, Rodgers J, Scholey AB, Ling J. 2001. Prospective memory, everyday cognitive failure and central executive function in recreational users of Ecstasy. Hum Psychopharmacol 16: 607-612. (Pubitemid 34036941)
16. Jansari A, Debreceni K, Bartfai A, Eriksson M. 2008. Swedish JAAM? Adaptation of a virtual reality assessment of dysexecutive syndrome to a new culture and language. Brain Impair 9(2): 220.
17. Jansari A, Agnew R, Duncombe S, Murphy L, Edginton T, Nikolla D. 2007. In search of an ecologically-valid measure of the dysexecutive syndrome: can virtual reality help in rehabilitation? Brain Impair 8.
18. Jansari A, Agnew R, Akesson K, Murphy L. 2004. The use of virtual reality to assess and predict real world executive dysfunction: can VR help for work-placement rehabilitation? Brain Impair 5: 110.
19. Johns MW. 1991. A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 14: 540-545.
20. Kalechstein AD, De La Garza R, Mahoney JJ, Fantegrossi WE, Newton TF. 2007. MDMA use and neurocognition: a meta-analytic review. Psychopharmacology 189: 531-537.
21. McGeorge P, Phillips LH, Crawford JR, et al. 2001. Using virtual environments in the assessment of executive dysfunction. Presence: Teleoperators Virt Environ 10: 375-383. (Pubitemid 33314770)
22. Miyake A, Friedman NP, Emerson MJ, Witzki AH, Howerter A, Wager TD. 2000. The unity and diversity of executive functions, and their contributions to complex "frontal lobe" tasks: a latent variable analysis. Cognit Psychol 41(1): 49-100.
23. Montgomery C, Fisk JE, Newcombe R, Murphy PN. 2005. The differential effects of ecstasy/polydrug use on executive components: shifting, inhibition, updating and access to semantic memory. Psychopharmacology 182: 262-276. (Pubitemid 41464619)
24. Montgomery C, Fisk JE. 2007. Everyday memory deficits in ecstasy-polydrug users. J Psychopharmacol 21: 709-717.
25. Montgomery C, Fisk JE. 2008. Ecstasy-related deficits in the updating component of executive processes. Hum Psychopharmacol 23: 495-511.
26. Morgan MJ. 1998. Memory deficits associated with recreational use of "ecstasy" (MDMA). Psychopharmacology 141: 30-36.
27. Morgan MJ. 2000. Ecstasy (MDMA): a review of its possible persistent psychological effects. Psychopharmacology 152: 230-248.
28. Murphy PN, Wareing M, Fisk JE, Montgomery C. 2009. Executive working memory deficits in abstinent ecstasy/MDMA users: a critical review. Neuropsychobiology 60: 159-175.
29. Newcombe RN. 2004. Does cannabis use cause psychosis? A study of trends in cannabis use and psychosis in England, 1995-2003. Adiktologie 4: 492-507.
30. Parrott AC, Lasky J. 1998. Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology 139: 261-268.
31. Parrott AC. 2004. Is ecstasy MDMA? A review of the proportion of ecstasy tablets containing MDMA, their dosage levels, and the changing perceptions of purity. Psychopharmacology (Berl) 173(3-4): 234-241.
32. Paine TA, Dringenberg HC, Olmstead MC. 2003. Effects of chronic cocaine on impulsivity: relation to cortical serotonin mechanisms. Behav Brain Res 147: 135-147.
33. Pugnetti L, Mendozzi L, Motta A, Cattaneo A, Barbieri E, Brancotti A. 1995. Evaluation and retraining of adults' cognitive impairments: which role for virtual reality technology? Comput Biol Med 25: 213-227.
34. Pugnetti L, Mendozzi L, Attree EA, et al. 1998. Probing memory and executive functions with virtual reality: past and present studies. CyberPsychol Behav 1: 151-162.
35. Raven J, Raven JC, Court JH. 1998.Manual for Raven's Progressive Matrices and Vocabulary Scales. Oxford Psychologists Press: Oxford, UK.
36. Ready RE, Stierman L, Paulsen JS. 2001. Ecological validity of neuropsychological and personality measures of executive functions. Clin Neuropsychol 15: 314-323.
37. Rendell P, Gray T, Henry J, Tolan A. 2007. Prospective memory impairment in "ecstasy" (MDMA) users. Psychopharmacology 194: 497-504.
38. Reneman L, Lavalaye J, Schmand B, et al. 2001. Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"). Arch Gen Psychiatr 58: 901-906.
39. Ricaurte GA, Martello AL, Katz JL, Martello MB. 1992. Lasting effects of (±)3,4-Methylenedioxymethamphetamine on central serotonergic neurons in non-human primates: neurochemical observations. J Pharmacol Exp Therapeut 261: 616-622.
40. Rodgers J. 2000. Cognitive performance amongst recreational users of "ecstasy". Psychopharmacology 151: 19-24.
41. Rogers G, Elston J, Garside R, et al. 2009. The harmful health effects of recreational ecstasy: a systematic review of observational evidence. Health Technol Assess 13: 3-9.
42. Sankoh AJ, Huque MF, Dubey SD. 1997. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 16: 2529-2542.
43. Solowij N, Hall W, Lee N. 1992. Recreational MDMA use in Sydney: a profile of ecstasy users and their experiences with the drug. Br J Addiction 87: 1161-1172.
44. Turner JJD, Juby K, Parrott AC. 1998. Spatial and object recognition performance of regular MDMA users assessed in virtual reality. J Psychopharmacol 12: A43.
45. Von Geusau NA, Stalenhoef P, Huizinga M, Snel J, Ridderinkhof KR. 2004. Impaired executive function in male MDMA ("ecstasy") users. Psychopharmacology 175: 331-341.
46. Wareing M, Fisk JE, Murphy P. 2000. Working memory deficits in current and previous users of MDMA ("ecstasy"). Br J Psychol 91: 181-188.
47. Wilson BA. 1993. Ecological validity of neuropsychological assessment: do neuropsychological indexes predict performance in everyday activities? Appl Prev Psychol 2: 209-215.
48. Zakzanis KK, Young D, Campbell Z. 2003. Prospective memory impairment in abstinent MDMA ("Ecstasy") users. Cognit Neuropsychiatr 8: 141-153.
49. Zakzanis KK, Campbell Z, Jovanovski D. 2007. The neuropsychology of ecstasy (MDMA) use: a quantitative review. Hum Psychopharmacol: Clin Exp 22: 427-435.